D. Lawson

发表

Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma

Robert W Cook, Pedram Gerami, R. Amaria, 2015, Clinical Cancer Research.

Complete response to high dose IL-2 ( HDIL-2 ) and enhanced IFN γ + Th 17 : T REG ratio in a melanoma patient

K. Delman, R. Kudchadkar, D. Lawson, 2022 .

20/20 in 2020: seeking clarity on the management of stage III melanoma in a rapidly changing treatment environment

S. Chandrasekaran, D. Lawson, 2020, Annals of translational medicine.

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E

G. Linette, A. Ribas, H. Tawbi, 2017, Melanoma research.

Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy

W. Curran, R. Ahmed, Judong Lee, 2020, Journal for ImmunoTherapy of Cancer.

Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy

A. Manatunga, D. Musselman, D. Lawson, 2009, Clinical trials.

Immediate breast reconstruction for stage III breast cancer using transverse rectus abdominis musculocutaneous (TRAM) flap

W. Wood, F. Nahai, L. Hughes, 1996, Annals of Surgical Oncology.

Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization

R. Kudchadkar, M. Elsayed, D. Lawson, 2020, CardioVascular and Interventional Radiology.

Reduction of Nodular Growth Pattern of Metastatic Uveal Melanoma after Radioembolization of Hepatic Metastases

A. Krasinskas, H. Grossniklaus, R. Kudchadkar, 2015, Ocular Oncology and Pathology.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

F. Marincola, P. Choyke, M. Merino, 2011, The New England journal of medicine.

Supplemental Information Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V 600 E Tumor Growth

F. Khuri, J. Arbiser, H. Khoury, 2022 .

Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.

G. Pagnoni, G. Berns, C. Nemeroff, 2007, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma

G. Linette, J. Sosman, G. Schwartz, 2017, Journal of Cancer Research and Clinical Oncology.

Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma

F. Khuri, S. Lonial, T. Owonikoko, 2020, British Journal of Cancer.

Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

E. Waller, M. Arellano, D. Jaye, 2009, Journal of immunotherapy.

Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition

S. Yeh, R. Kudchadkar, R. Swerlick, 2022, Frontiers in Oncology.

Retinopathy associated with high-dose interferon alfa-2b therapy.

P. Sternberg, T. Aaberg, D. Lawson, 2001, American journal of ophthalmology.

Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials

T. Owonikoko, S. Ramalingam, V. Master, 2019, Investigational New Drugs.

Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases

K. Patel, F. Khosa, S. Shoukat, 2017, American journal of clinical oncology.

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series

E. Lipson, N. Ibrahim, K. Shirai, 2014, Journal of Immunotherapy for Cancer.

A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma.

P. Hwu, L. Riley, D. Schwartzentruber, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors

G. Sica, F. Khuri, S. Lonial, 2020, Clinical Cancer Research.

Paroxetine for the prevention of depression induced by high-dose interferon alfa.

A K Manatunga, C. Nemeroff, A. Miller, 2001, The New England journal of medicine.

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma

M. Atkins, J. Sosman, G. Weiss, 2008, Cancer.

Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

F. Marincola, P. Choyke, M. Merino, 2011 .

Exosome-containing preparations from post-irradiated mouse melanoma cells delay melanoma growth in vivo by a natural killer cell-dependent mechanism.

R. Ahmed, Zhentian Li, W. Dynan, 2020, International journal of radiation oncology, biology, physics.

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced an

M. Atkins, J. Kirkwood, L. Butterfield, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy

T. Owonikoko, S. Ramalingam, V. Master, 2018, Cancer.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

G. Linette, J. Wolchok, J. Sosman, 2014, JAMA.

E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma.

J. Kirkwood, M. Ernstoff, K. Margolin, 2010 .

Clinical Correlation between Acute Exudative Polymorphous Paraneoplastic Vitelliform Maculopathy and Metastatic Melanoma Disease Activity: A 48-month Longitudinal Case Report

Nieraj Jain, Joshua Robinson, D. Lawson, 2020, Ocular immunology and inflammation.

Plasma homocysteine and immune activation in patients with malignant melanoma undergoing treatment with IFN-α

C. Nemeroff, D. Fuchs, Andrew H. Miller, 2004 .

Complete response to high-dose IL-2 and enhanced IFN&ggr;+Th17 : TREG ratio in a melanoma patient

K. Delman, M. Ford, R. Kudchadkar, 2016, Melanoma research.

Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.

D. Murray, S. Graham, D. Levitt, 1991, Archives of surgery.

Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).

G. Linette, J. Wolchok, J. Sosman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utility of Lymph Node Assessment for Atypical Spitzoid Melanocytic Neoplasms

K. Delman, G. Carlson, M. Durham, 2010, Annals of Surgical Oncology.

The emerging role of radiotherapy for desmoplastic melanoma and implications for future research

K. Delman, K. Patel, R. Kudchadkar, 2015, Melanoma research.

Melanoma Growth Stimulatory Activity in Primary Malignant Melanoma: Prognostic Significance

C. Cohen, P. DeRose, D. Lawson, 2002, Modern Pathology.

Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas.

R. Fine, A. Richmond, J. Priest, 1986, The Journal of investigative dermatology.

Role of Radiation Therapy as Immune Activator in the Era of Modern Immunotherapy for Metastatic Malignant Melanoma

D. Lawson, B. Pollack, Mohammad K. Khan, 2015, American journal of clinical oncology.

Evaluation of transsphenoidal hypophysectomy in the management of patients with advanced malignant melanoma

V. Camp, G. Tindall, D. Nixon, 1983, Cancer.

Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin

D. Lawson, R. York, Jeanine McKay, 1983, Cancer.

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.

J. Janopaul-Naylor, R. Kudchadkar, D. Qian, 2021, The Lancet. Oncology.

Interferon-alpha–induced changes in tryptophan metabolism relationship to depression and paroxetine treatment

C. Nemeroff, D. Fuchs, Andrew H. Miller, 2003, Biological Psychiatry.

Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients

J. Ho, L. Ferris, K. Covington, 2018, BMC Cancer.

Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.

S. O’Day, L. Hutchins, R. Weber, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma

D. Schadendorf, M. Gore, J. Thompson, 2011, British Journal of Cancer.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

V. Sondak, R. Sullivan, M. Atkins, 2018, Journal of Immunotherapy for Cancer.

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

John Kirkwood, Eric Whitman, Lee Cranmer, 2011, Investigational New Drugs.

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

M. Atkins, J. Kirkwood, L. Butterfield, 2017, Clinical Cancer Research.

Balancing Inflammation: The Link between Th17 and Regulatory T Cells

K. Delman, M. Ford, R. Kudchadkar, 2016, Mediators of inflammation.

Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.

F. Khuri, S. Lonial, O. Abdel-Wahab, 2017, Cell metabolism.

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

T. Owonikoko, S. Ramalingam, V. Master, 2019, BMC Cancer.

A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.

J. Kirkwood, K. Lewis, W. Samlowski, 2007 .

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

F. Hodi, S. O’Day, T. Guthrie, 2016, Journal of Immunotherapy for Cancer.

Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.

R. Ahmed, K. Patel, R. Kudchadkar, 2015, Neuro-oncology.

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

V. Sondak, M. Atkins, J. Sosman, 2013, Nature Reviews Clinical Oncology.

Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy

G. Pagnoni, G. Berns, C. Nemeroff, 2007, Neuropsychopharmacology.

Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

C. Nemeroff, Andrew H. Miller, C. Raison, 2003, The American journal of psychiatry.

BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy

K. Patel, H. Danish, D. Lawson, 2016, OncoTargets and therapy.

A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma.

M. Ernstoff, M. Milhem, Joseph I. Clark, 2015 .

Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.

G. Sica, F. Khuri, T. Owonikoko, 2016, The Journal of molecular diagnostics : JMD.

Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.

L. Ferris, R. Amaria, K. Delman, 2015, Journal of the American Academy of Dermatology.

Preparation of a monoclonal antibody to a melanoma growth‐stimulatory activity released into serum‐free culture medium by Hs0294 malignant melanoma cells

D. S. Gordon, A. Richmond, D. Gordon, 1987, Journal of cellular biochemistry.

Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions

C. Nemeroff, Andrew H. Miller, D. Musselman, 2002, Neuropsychopharmacology.

Radiologic and Histopathologic Correlation of Different Growth Patterns of Metastatic Uveal Melanoma to the Liver.

H. Grossniklaus, Jenny J. Yang, P. Mittal, 2017, Ophthalmology.

Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.

Maria L. Wei, Eric A. Smith, J. Stein, 2020, JAMA dermatology.

P. Hwu, L. Riley, D. Schwartzentruber, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Choices in adjuvant therapy of melanoma.

D. Lawson, 2005, Cancer control : journal of the Moffitt Cancer Center.

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

G. Linette, J. Hainsworth, K. Flaherty, 2014, Cancer journal.

Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).

K. Delman, M. Ford, R. Kudchadkar, 2018 .

Rising Incidence of Mucosal Melanoma of the Head and Neck in the United States

T. Owonikoko, D. Marcus, J. Beitler, 2012, Journal of skin cancer.

Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma

R. Gonzalez, S. O’Day, L. Hutchins, 2007 .

A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma

J. Kirkwood, K. Lewis, W. Samlowski, 2007 .

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.

M. Atkins, J. Kirkwood, P. Chapman, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon Alfa‐2b or Not 2b? Significant Differences Exist in the Decision‐Making Process between Melanoma Patients Who Accept or Decline High‐Dose Adjuvant Interferon Alfa‐2b Treatment

Suephy C. Chen, E. Veledar, C. Washington, 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

T. Owonikoko, S. Ramalingam, V. Master, 2019, BMC Cancer.

Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study

R. Dhanasekaran, Hyun S Kim, D. Lawson, 2017, American journal of clinical oncology.

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

A. Abernethy, A. Ribas, R. Gonzalez, 2012, Journal of Translational Medicine.

Plasma inter‐α‐trypsin inhibitor‐related urinary glycoprotein EDC 1 inhibits the growth of a Burkitt's lymphoma cell line

J. Travis, D. Lawson, D. Lawson, 1990 .

Melanoma Cell Intrinsic GABAA Receptor Enhancement Potentiates Radiation and Immune Checkpoint Inhibitor Response by Promoting Direct and T Cell-Mediated Antitumor Activity.

D. P. Pomeranz Krummel, A. Jenkins, M. Medvedovic, 2020, International journal of radiation oncology, biology, physics.

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

M. Ernstoff, B. Taback, J. Lutzky, 2018, Journal of Immunotherapy for Cancer.

Outcome with stereotactic radiosurgery (SRS) and ipilimumab (Ipi) for malignant melanoma brain metastases.

D. Marcus, M. Rizzo, D. Lawson, 2013 .

2-year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM)

R. Gonzalez, S. O’Day, L. Hutchins, 2008 .

The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.

F. Khuri, S. Lonial, O. Abdel-Wahab, 2018, Molecular cell.

BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis

K. Patel, R. Kudchadkar, D. Lawson, 2016, Melanoma research.

T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient

W. Curran, D. Douek, A. Kamphorst, 2018, Cancer Immunology, Immunotherapy.

Update on the systemic treatment of malignant melanoma.

D. Lawson, 2004, Seminars in oncology.

Melanoma quality of life: pilot study using utility measurements.

K. Puttgen, P. Kolm, Suephy C. Chen, 2011, Archives of dermatology.

Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases.

J. Olson, W. Curran, D. P. Pomeranz Krummel, 2020, International journal of radiation oncology, biology, physics.

Prognostic Factors for Overall Survival After Radiosurgery for Brain Metastases From Melanoma

K. Delman, I. Crocker, G. Carlson, 2014, American journal of clinical oncology.

Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab

D. Lawson, A. Voloschin, Vita Kesner, 2018, Journal of Immunotherapy for Cancer.

Phase 1, 2 trial of concurrent anti-PD1 and stereotactic radiosurgery for melanoma and non-small cell lung cancer brain metastases (NCT02858869).

T. Owonikoko, S. Ramalingam, R. Ahmed, 2021 .

Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases.

C. Anker, R. Kudchadkar, D. Lawson, 2020, Neurosurgery.

Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.

S. Yeh, C. Bergstrom, D. Lawson, 2015, Journal of immunotherapy.

Mucosal Melanoma Of The Head and Neck: A Population-based Analysis, 1973 - 2007

T. Owonikoko, D. Marcus, J. Beitler, 2011 .

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy

Shannon C. Trotter, J. Stein, R. Dellavalle, 2017, Melanoma management.

Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing.

Maria L. Wei, Rajan P. Kulkarni, J. Stein, 2023, JAMA dermatology.

Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.

P. Tamayo, S. Fröhling, D. Brat, 2015, Molecular cell.

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy

T. Owonikoko, S. Ramalingam, V. Master, 2019, The oncologist.

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.

T. Owonikoko, S. Ramalingam, V. Master, 2019, The oncologist.

HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers

F. Khuri, S. Lonial, O. Abdel-Wahab, 2017, The Journal of Biological Chemistry.

Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study.

H. Grossniklaus, M. Lynn, S. Dithmar, 2000, Archives of ophthalmology.

Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials

T. Owonikoko, S. Ramalingam, V. Master, 2020, Cancer.

Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.

D. Schuster, R. Dhanasekaran, Hyun S Kim, 2012, Journal of vascular and interventional radiology : JVIR.

A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma

Jeffrey W. Clark, M. Atkins, J. Sosman, 2005 .

The Impact of Escitalopram on IL-2-Induced Neuroendocrine, Immune, and Behavioral Changes in Patients with Malignant Melanoma: Preliminary Findings

Ming Wang, Q. Long, Andrew H. Miller, 2013, Neuropsychopharmacology.

A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

C. Nemeroff, A. Manatunga, D. Musselman, 2006, The Journal of clinical psychiatry.

Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients

K. Delman, M. Ford, R. Kudchadkar, 2016, Journal of immunotherapy.

A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).

F. Hodi, T. Guthrie, A. Salama, 2015 .

The prognostic utility of LDH and disease-specific graded prognostic assessment for melanoma brain metastases.

K. Delman, I. Crocker, G. Carlson, 2011, Journal of Clinical Oncology.

Phase 2 trial of talabostat in stage IV melanoma

B. Redman, M. Ernstoff, T. Gajewski, 2005 .

The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.

K. Delman, K. Patel, T. Gillespie, 2016, Melanoma research.

The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis

K. Delman, K. Patel, T. Gillespie, 2016 .

Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: An updated analysis.

K. Delman, R. Kudchadkar, D. Lawson, 2019, Journal of Clinical Oncology.

Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): Subgroup analysis by prior chemotherapy

R. Gonzalez, L. Hutchins, R. Weber, 2008 .

Post-Irradiated Tumor-Derived Exosomes Lead to Melanoma Tumor Growth Delay, Potentially Mediated by Death Associated Molecular Pattern (DAMPs) Proteins

R. Ahmed, Zhentian Li, W. Dynan, 2018, International Journal of Radiation Oncology*Biology*Physics.